anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
VUMERITY may decrease lymphocyte counts. In the MS placebo-controlled trials with dimethyl fumarate (which has the same active metabolite as VUMERITY), mean lymphocyte counts decreased by approximately 30% during the first year of treatment with dimethyl fumarate and then remained stable. Four weeks after stopping dimethyl fumarate, mean lymphocyte counts increased but did not return to baseline. Six percent (6%) of dimethyl fumarate patients and <1% of placebo patients experienced lymphocyte counts <0.5 × 109/L (lower limit of normal 0.91 × 109/L). The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with dimethyl fumarate or placebo, respectively. There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8 × 109/L or ≤0.5 × 109/L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5 × 109/L for 3.5 years) [see Warnings and Precautions (5.2)]. 

In controlled and uncontrolled clinical trials with dimethyl fumarate, 2% of patients experienced prolonged, severe lymphopenia, (defined as lymphocyte counts <0.5 x 109/L for at least six months); in this group of patients, the majority of lymphocyte counts remained <0.5 x 109/L with continued therapy. In these patients with prolonged, severe lymphopenia, the median time for lymphocyte counts to return to normal after discontinuing dimethyl fumarate was 96.0 weeks.

In these controlled and uncontrolled clinical studies, among patients who did not experience prolonged, severe lymphopenia during treatment, the median times for lymphocyte counts to return to normal after discontinuing dimethyl fumarate were as follows:

  * 4.3 weeks in patients with mild lymphopenia (lymphocyte count ≥0.8 x 109/L) at discontinuation,
  * 10.0 weeks in patients with moderate lymphopenia (lymphocyte count 0.5 to <0.8 x 109/L) at discontinuation, and
  * 16.7 weeks in patients with severe lymphopenia (lymphocyte count <0.5 x 109/L) at discontinuation.



Neither VUMERITY nor dimethyl fumarate have been studied in patients with preexisting low lymphocyte counts. 

Obtain a complete blood count (CBC), including lymphocyte count, before initiating treatment with VUMERITY, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated. Consider interruption of VUMERITY in patients with lymphocyte counts less than 0.5 × 109/L persisting for more than six months. Given the potential for delayed recovery of lymphocyte counts, continue to obtain lymphocyte counts until their recovery if VUMERITY is discontinued or interrupted because of lymphopenia. Consider withholding treatment from patients with serious infections until resolution. Decisions about whether or not to restart VUMERITY should be individualized based on clinical circumstances.
PURPOSE:To obtain an antitumor agent, containing S-(alpha,beta-dicarboxyethyl) glutathione or an ester derivative thereof as an active ingredient and having powerful antitumor action with high safety. CONSTITUTION:An antitumor agent containing a compound expressed by the formula (R is the same or different H or lower alkyl) or a pharmacologically acceptable salt thereof as an active ingredient. The aforementioned antitumor agent it useful for treating malignant tumor, e.g. solid cancer, such as gastric, hepatic or pulmonary cancer, or blood cancer, such as leukemia or Hodgkin's diseases. The dose thereof is within the range of 10-500mg for an adult administered once a day in the case of an injection, 10-1000mg for an adult at a time administered several times a day in the case of an internal medicine and 10-500mg administered once a day in the case of a suppository. The compound expressed by the formula is obtained by extraction thereof from a yeast or bovine crystalline lens, isolating and purifying the resultant extract or reacting glutathione with equimolar amount of maleic acid.
When available, the clinical microbiology laboratory should provide cumulative results of the in vitro susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.

Dilution techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth or agar) (1) or equivalent with standardized inoculum concentrations and standardized concentrations of nitrofurantoin powder. The MIC values should be interpreted according to the criteria provided in Table 1.

Diffusion techniques

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure (2) requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 300 mcg of nitrofurantoin to test the susceptibility of microorganisms to nitrofurantoin. The disk diffusion interpretive criteria are provided in Table 1.

A report of Susceptible indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the urine reaches the concentrations usually achievable. A report of Intermediate indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone, which prevents small, uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the urine reaches the concentrations usually achievable; other therapy should be selected.

Quality Control: Standardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the test procedures (3). Standard nitrofurantoin powder should provide the following range of values noted in Table 2.
The present invention relates to medicine for treating coronary diseases and a production method of the medicine. The medicine contains acanthopanax flower, immature fruit, pleuropterus cordatus, red sage root, corydalis tuber and cinnabar. The present invention can be processed into powder preparation, granular preparation and tablet preparation, and has a simple production method. The medicine is used for treating diseases such as myocardial ischemia, angina pectoris, arrhythmia, myocardial infarction and myocardial sclerosis, and the diseases are caused by stenosis and blockage resulting from coronary atherosclerosis. The medicine has the advantages of easy use, short course of treatment, obvious effect, and no toxicity or side effect for long-term administration. An effective rate is more than 90%, and a recovery rate is more than 70%.
The present invention relates to a traditional Chinese ointment for treating rheumatism, which is composed of traditional Chinese medicine components and ointment components. The present invention is characterized in that the traditional Chinese medicine componets contain traditional Chinese medicines for treating rheumatism, such as curare, rhizoma arisaematis and kusnezoff monkshood root, pinellia tuber and fresh ginger. The addition of the pinellia tuber and the match of the kusnezoff monkshood root do not increase poison but greatly enhance the action of acesodyne. The addition of the fresh ginger can promote the absorption of the traditional Chinese medicines through the skin, so the treatment effect of the traditional Chinese medicines is enhanced. The ointment components contain Baishan soil and fine river sand, and gypsum powder and sheet alkali capable of releasing heat in water. The gypsum powder is prepared into ointments by water while the medicine is used, the traditional Chinese medicine powder is uniformly spread on the surface of the ointments, and then the ointments are spread on disease regions or relevant acupoints. The defects of preheating and short heating time of mud treatment can be avoided, and various trace elements in the Baishan soil and effective components of the traditional Chinese medicines can be rapidly impregnated into a human body. The ointment has the functions of heat treatment, dispelling wind and dampness, activating blood circulation to dissipate blood stasis, removing stasis, relieving pain and softening spur and is suitable for treating diseases of rheumatism, arthritis, periarthritis humeroscapularis, cervical spondylosis, lumbar disc protrusion, etc., and the effective rate is 97%.
Participants in Arm B received four cycles of rituximab 375 mg/m\^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
PURPOSE: The potential of uniportal video-assisted thoracic surgery (U-VATS) to reduce chronic pain after thoracic surgery (CPTS) compared to open thoracotomy (OT) remains unexplored. This prospective study aims to assess the incidence of CPTS following U-VATS or OT and identify associated risk factors.
METHODS: Patients undergoing thoracic surgery were recruited from March 2021 to March 2022, categorized by surgical approach (U-VATS vs. OT). Standard clinical protocols for surgery, anesthesia, and analgesia were followed. Pain symptoms were assessed using the Short-form McGill Pain Questionnaire, with follow-ups up to 6 months. Perioperative factors influencing CPTS at 3 months were analyzed through univariate and multivariate methods.
RESULTS: A total of 694 patients were analyzed. Acute pain after thoracic surgery (APTS) was significantly less severe in the U-VATS group (p < 0.001). U-VATS patients exhibited a lower incidence of CPTS at 3 months (63.4% vs. 80.1%, p < 0.001), with reduced severity among those experiencing CPTS (p = 0.007) and a decreased occurrence of neuropathic pain (p = 0.014). Multivariate analysis identified OT incision, moderate to severe APTS (excluding moderate static pain at 24 h postoperative), nocturnal surgery, and lung surgery as risk factors for CPTS.
CONCLUSION: This study underscores the potential of U-VATS to reduce both the incidence and severity of CPTS at 3 months compared to OT. Furthermore, it highlights risk factors for CPTS, including OT incision, inadequately managed APTS, lung surgery, and nocturnal surgery. These findings emphasize the importance of considering surgical approach and perioperative pain management strategies to mitigate the burden of CPTS.
Unscheduled and Scheduled Bleeding and Spotting   
Women using TWIRLA may experience unscheduled (breakthrough or intracyclic) bleeding and spotting, especially during the first three months of use. Bleeding irregularities may resolve over time or by changing to a different contraceptive product. If bleeding persists or occurs after previously regular cycles on TWIRLA, evaluate for causes such as pregnancy or malignancy.

Based on women’s electronic diaries from a clinical trial evaluating the safety and efficacy of TWIRLA, the proportion of subjects reporting unscheduled bleeding per 28-day cycle decreased over time. At cycle 1 and 2, 60.4% and 52.6%, respectively reported unscheduled bleeding and/or spotting. At cycle 13, 42.3% of women reported unscheduled bleeding and/or spotting. Women reported a mean number of unscheduled bleeding/spotting days per month that generally decreased over the 13 cycles and was a mean of 1.6 days in Cycle 13. A total of 45 women (2.2%) discontinued the study prematurely due to menstrual disorders including metrorrhagia, vaginal hemorrhage, menorrhagia, dysmenorrhea, irregular menstruation, dysfunctional uterine bleeding, and menstrual disorder [see Clinical Trial Experience (6.1) and Clinical Studies (14)].

Amenorrhea and Oligomenorrhea   
Women who use TWIRLA may experience absence of scheduled (withdrawal) bleeding, even if they are not pregnant. Based on electronic patient diaries from the clinical trial, the percentages of women with no bleeding and/or spotting days (amenorrhea) in a cycle ranged from 6.3% to 11.9% over 13 cycles [see Clinical Trial Experience (6.1) and Clinical Studies (14)].

If scheduled bleeding does not occur, consider the possibility of pregnancy. If the woman has not adhered to the prescribed dosing schedule (missed days of active therapy or started her TDS on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and perform appropriate diagnostic measures. If the woman has adhered to the prescribed dosing schedule and misses two consecutive periods, rule out pregnancy.

After discontinuation of TWIRLA, amenorrhea or oligomenorrhea may occur, especially if these conditions were pre-existent.
<P>PROBLEM TO BE SOLVED: To provide a knowledge presenting system in nursing work capable of positively confirming whether or not a nurse has carried out treatment.  <P>SOLUTION: In the knowledge presenting system 10, a worksheet 28 is printed on electronic paper 20, and it is delivered to a nurse. A treatment schedule section 282 and a check section 283 attached to it are printed in the worksheet 28, and advice data with respect to treatment scheduled to be carried out quoted in the schedule section 282 is added to an advice section 285, and printed. A server 12 detects existence or nonexistence of a mark in the check section. By this, since not only treatment items, but also advice items are presented to the nurse, the treatment item can minimize mistakes. Since it can be judged whether or not the treatment items described in the worksheet are finished on the basis of existence or nonexistence of a mark in the check section attached to the treatment items, it can be positively confirmed whether or not the treatment items have been carried out.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Endodontic formulations and methods of use are provided. The formulations can be irrigant formulations for irrigating a root canal using an effective amount of Cysteamine or a Cysteamine derivative. The effective amount can be effective to inhibit the proliferation of at least one bacterial infection in the root canal patient. The effective amount can be effective to produce a percent reduction in  Enterococcus faecalis  in the canal wall of the patient of about 60% or more when administered to the patient. The effective amount can be effective to produce a percent reduction in  Fusobacterium nucleatum  in the canal wall of the patient of about 65% or more when administered to the patient. The formulations can be decalcifying formulations for reducing a calcification of a tissue in a root canal of a patient in need thereof. The decalcifying ability can be greater than a corresponding formulation such as EDTA and/or NaOCl.
FIELD: organic chemistry. SUBSTANCE: product: water-insoluble iodinated esters of the formula (I)   with the corresponding radical values. Molecule has at least one iodine atom and in the process of metabolism converts to compounds that are soluble in organism fluids and physiologically acceptable. Proposed compounds were used for roentgen and ultrasonic visualization, in part, liver and spleen. EFFECT: improved method of synthesis. 3 cl
FIELD: cosmetology. SUBSTANCE: invention deals with cosmetic composition (deodorant) in hard or liquid form containing antiperspiring-active aluminium-containing substance (aluminium hydrochloride in solvent), and also polyethenylformamide as a thickening agent. Said composition may be antiperspiring one, when it contains antiperspiring- effective quantity of aluminium-containing material, and it may be applied in armpits region for reducing perspiration. Ammonium acetate may be included in said composition for its hardening. Composition is applied by extrusion of gel through pores or slits in container cover. Composition may be light and transparent. EFFECT: stability of compositions in acid media, and their simplification for production. 37 cl, 15 ex
The mucopolysaccharidoses are a group of inherited lysosomal storage disorders. Lysosomes function as the primary digestive units within cells. Enzymes within lysosomes break down or digest particular nutrients, such as certain carbohydrates and fats. In individuals with MPS disorders, deficiency or malfunction of specific lysosomal enzymes lead to an abnormal accumulation of certain complex carbohydrates (mucopolysaccharides or glycosaminoglycans) in the arteries, skeleton, eyes, joints, ears, skin and/or teeth. These accumulations may also be found in the respiratory system, liver, spleen, central nervous system, blood, and bone marrow. This accumulation eventually causes progressive damage to cells, tissues, and various organ systems of the body. There are several different types and subtypes of mucopolysaccharidosis. These disorders, with one exception, are inherited as autosomal recessive traits and all vary in their clinical phenotype. Within our clinical trial we focus on MPS type IV.

Morquio syndrome (mucopolysaccharidosis type IV; MPS IV) is a mucopolysaccharide storage disease that exists in two forms (Morquio syndromes A and B) and occurs because of a deficiency of the enzymes N-acetyl-galactosamine-6-sulfatase and beta-galactosidase, respectively. A deficiency of either enzyme leads to the accumulation of mucopolysaccharides in the body, abnormal skeletal development, and additional symptoms. In most cases, individuals with Morquio syndrome have normal intelligence. The clinical features of MPS IV-B are less severe than those associated with MPS IV-A. Symptoms may include growth retardation, a prominent lower face, an abnormally short neck, knees that are abnormally close together (knock knees or genu valgum), flat feet, abnormal sideways and front-to-back or side-to-side curvature of the spine (kyphoscoliosis), abnormal development of the growing ends of the long bones (epiphyses) resulting in dwarfism, and/or a prominent breast bone (pectus carinatum) as well as bell shaped chest. Though the CNS and peripheral nerves are primarily not affected the bone defects may result in neurological symptoms such as spinal cord compression. Hearing loss, weakness of the legs, and/or additional abnormalities may also occur.

The goal of the study is to prepare a cell culture from patients affected with Morquio disease in order to identify novel pathways and proteins involved in disease progression that allow for an earlier diagnosis (i.e. before symptom onset) and that are suitable targets for an individualized therapeutic approach able to address not only the hepatic form, but also the neurologic form of the disease, which is less responsive to the current therapeutic approaches.
FIELD: medicine. SUBSTANCE: infusion of Parmelia is proposed for usage, ratio raw materials:extragent being 50:1000. Said infusion is used by 50 ml 4 times a day for 30 min before meal within 18 days. Proposed infusion is used simultaneously with vicaline, penicillin and vitamins B 1 and B 6 . Complete epithelization is 71.4 %. EFFECT: decreases treatment time, increases frequency of complete epithelization. 1 tbl
Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy, PET/CT or MRI scans, and blood sample collection throughout the study.
The present invention relates to an isolated vNAR protein comprising a CDR1 with an amino acid sequence selected from SEQ. ID NOT. 1, SEQ. ID NOT. 5, or its substantially similar variants, and a CDR3 with an amino acid sequence selected from SEQ. ID NOT. 2, SEQ. ID NO. 6, or substantially similar variants thereof. Said composition recognizes the human glycated hemoglobin beta-subunit target or biomarker with at least one vNAR protein according to the present invention. Also, it relates to an ex vivo method for recognizing human glycated hemoglobin beta-subunit target or biomarker, providing a blood sample from a suspected diabetes patient, contacting the blood sample, and detecting the presence of glycated hemoglobin.
Background and Objectives: Recurrent pregnancy loss (RPL) is a multifactorial condition, encompassing genetic, anatomical, immunological, endocrine, as well as infectious and environmental factors; however, the etiology remains elusive in a substantial number of cases. Genetic factors linked to RPL include parental karyotype abnormalities (e.g., translocations, inversions, copy number variants), an increase in sperm aneuploidy, fetal microchimerism, severe skewing of X chromosome inactivation, and various gene polymorphisms. Our study aims to explore the value of routine conventional parental karyotyping in couples with RPL. Materials and Methods: A total of 213 couples (426 individuals) with a history of RPL were enrolled in this retrospective study. The peripheral blood samples included in this study were referred to the Human Genomics Laboratory of the University of Medicine and Pharmacy in Craiova, Romania, for conventional cytogenetic analysis between January 2013 and December 2023, by the Outpatient Medical Genetics Clinic of the Emergency Clinical County Hospital of Craiova. Chromosome analysis was performed using standard protocols and karyotypes were reported according to ISCN. Results: Out of 426 patients provided with conventional G-banded chromosome analysis, 410 had a normal karyotype (96.2%) and 16 had chromosome abnormalities (3.8%). The most common chromosomal abnormalities were reciprocal and Robertsonian translocations, with chromosomes 8, 11, 14, and 21 being most frequently involved. A single numerical anomaly was detected (47,XYY). One or multiple chromosomal polymorphisms were identified in 104 subjects (24.4%). In addition, we conducted a stratified analysis of the unselected group and detected chromosome abnormalities in only four cases (0.94%). Conclusions: Our results are consistent with recommendations for paternal karyotyping after an individual risk assessment in instances such as a previous live birth with congenital anomalies and/or the detection of unbalanced chromosomes or a translocation in product of conception or chorionic villi/amniotic fluid samples. In the absence of a positive history, blindly karyotyping couples may prove too expensive and labor intensive, while providing no information on fertility status or live birth rates.